SI-BONE (SIBN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced at 8:00 A.M. Pacific Time on June 4th, 2026, via a virtual platform.
Board members, executive officers, independent auditor, and legal counsel were introduced.
The agenda included three proposals: election of directors, ratification of auditor, and advisory vote on executive compensation.
Corporate governance
Inspector of Election appointed to oversee voting and ensure impartiality.
Quorum established with proxies for 87.93% of outstanding shares.
Stockholder list and notice of meeting were made available and certified.
Shareholder proposals
Election of two directors to serve until the 2029 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation as disclosed in the proxy statement.
Latest events from SI-BONE
- Innovation, partnerships, and reimbursement changes set the stage for multi-year growth acceleration.SIBN
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 saw 11.2% revenue growth, margin strength, and raised full-year guidance.SIBN
Q1 202611 May 2026 - Double-digit growth, record profitability, and innovation drive expansion in a $3.5B+ market.SIBN
Corporate presentation11 May 2026 - Strong revenue growth, improved profitability, and robust governance mark this year's proxy.SIBN
Proxy filing22 Apr 2026 - Annual meeting to vote on directors, auditor, and Say-on-Pay, with board support for all.SIBN
Proxy filing21 Apr 2026 - Strategic innovation and partnerships drive growth and market expansion through 2028.SIBN
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 20% revenue growth and positive adjusted EBITDA in 2025; strong 2026 outlook ahead.SIBN
Q4 202523 Feb 2026 - Market leader in sacropelvic devices, accelerating growth with new launches and nearing profitability.SIBN
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 2024 revenue up 20%, net loss narrows, 2024 guidance raised, and positive EBITDA expected.SIBN
Q2 20242 Feb 2026